LASCCO
LASCCO SA is a Swiss diagnostics company that developed the Pancreatic Stone Protein (PSP) sepsis biomarker and generates revenue exclusively through licensing partnerships with Abionic SA (global point-of-care) and Fapon (China CLIA platform), serving hospital ICUs and emergency departments.
- Company typePrivate
- Founded2007
- HeadquartersGeneva, Switzerland
- Headcount5,001–10,000
- GTM typeB2B
- OfferingServices
What LASCCO does
LASCCO SA is a privately held Swiss diagnostics company headquartered in Epalinges, Switzerland, that developed Pancreatic Stone Protein (PSP), a novel sepsis biomarker measured from a drop of blood to provide early warning of sepsis risk in high-risk hospital patients. The PSP biomarker correlates with sepsis progression and remains accurate in confounding clinical settings such as burn injuries, post-trauma, and post-surgery, with more than 80 peer-reviewed publications supporting its clinical evidence base. LASCCO's commercial offering centers on a sepsis diagnostics suite comprising two productized formats: the IVD CAPSULE PSP, a point-of-care capsule commercialized by Abionic SA, and the PSP CLIA Solution, a chemiluminescent immunoassay format developed in collaboration with Fapon for the Chinese market.
The company operates an asset-light, licensing-only business model: it generates revenue exclusively through royalty arrangements with its commercial partners rather than through direct sales, distribution, or marketing. LASCCO has licensed global commercial rights to Abionic SA, which has secured FDA 510(k) clearance (October 2024), EU IVDR certification, EU CE mark, and Australian TGA certification for the IVD CAPSULE PSP. In October 2023, LASCCO and Abionic entered a strategic partnership with Fapon to bring the PSP biomarker onto Fapon's CLIA analyzer platform exclusively for China. End-customers are hospital healthcare providers — primarily intensive care units, emergency departments, and burn/trauma units — addressing the clinical problem of late sepsis recognition, which drives more than 11 million deaths annually and represents the single most expensive condition treated in hospitals globally.
LASCCO firmographics
Firmographics- Name
- LASCCO
- Legal name
- LASCCO SA
- Website
- https://lascco.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- LASCCO SA is a Swiss diagnostics company that developed the Pancreatic Stone Protein (PSP) sepsis biomarker and generates revenue exclusively through licensing partnerships with Abionic SA (global point-of-care) and Fapon (China CLIA platform), serving hospital ICUs and emergency departments.
- Ownership category
- akta.pro rank
LASCCO industry classification
Industry- Product category
- In-Vitro Diagnostics (Sepsis Biomarkers)
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM)
- akta.pro secondary industry
- Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE)
Keywords
Where LASCCO is headquartered
LocationHeadquarters
- HQ city
- Geneva
- HQ country
- Switzerland
- HQ region
- Europe
Offices1 record
Markets served
LASCCO business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations
Revenue model
- Licensing Royalties: LASCCO generates revenue by licensing commercial rights for its PSP diagnostic test to strategic partners. The company licensed PSP commercial rights to Abionic SA and entered into a strategic partnership with Fapon for the Chinese market.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels1 record
LASCCO product offering
Product offeringCore offering
LASCCO SA develops and owns the intellectual property for the Pancreatic Stone Protein (PSP), a biomarker used in a rapid diagnostic test for the early detection of sepsis. The company licenses the commercial rights to its PSP biomarker to Abionic SA for global commercialization and to Fapon for the Chinese market, earning royalties from these partnerships.
Product overview
LASCCO has developed PSP (Pancreatic Stone Protein), a novel sepsis biomarker diagnostic test. The company's product portfolio consists of the core PSP biomarker technology and its commercialized derivatives: the IVD CAPSULE PSP (commercialized by Abionic SA, FDA-cleared) and the PSP CLIA solution (commercialized by Fapon for the Chinese market). These products form a sepsis diagnostics suite that provides rapid, lab-quality results from small blood samples to accelerate time-to-recognition of this life-threatening condition.
Differentiator
Problem solved
Functional benefit
Products and services
- Pancreatic Stone Protein (PSP) Sepsis Biomarker IP Proprietary Pancreatic Stone Protein (PSP) biomarker used in a rapid blood-based test for the early detection of sepsis. Licensed by LASCCO SA to IVD platform manufacturers such as Abionic SA (global) and Fapon (China), enabling them to offer a regulatory-cleared sepsis diagnostic to hospitals and clinical laboratories.
Quantifiable outcome
- 50 million sepsis cases per year globally
- +1 more outcomes
Companies that use LASCCO
Customer profileSegments1 record
Ideal customer profiles1 record
LASCCO technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
LASCCO partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Abionic SAcoreAbionic SA holds the commercial license rights for LASCCO's PSP diagnostic test. The IVD CAPSULE PSP test developed by Abionic has received FDA 510(k) clearance and is certified under EU IVDR and CE. This is a core licensing partnership where Abionic commercializes the PSP technology.
- FaponcoreLASCCO and Abionic entered into a strategic partnership with Fapon in October 2023 to bring the PSP solution to China. Fapon is developing the PSP solution on its chemiluminescent immunoassay (CLIA) analyzer specifically for the Chinese market. This is a regional strategic collaboration for market expansion.
Scale indicators4 records
Recent moves5 records
Expansion highlights4 records
LASCCO competitors and assessment
Company assessmentPeers
Broad incumbents
- Roche Diagnostics: Roche Diagnostics operates one of the largest IVD platforms globally, including Elecsys sepsis and infectious-disease panels on central lab analyzers. It is comparable as a broad incumbent whose installed immunoassay base overlaps with the hospital workflow that PSP targets.
- bioMérieux: bioMérieux is a global leader in microbiology and clinical diagnostics, with procalcitonin (VIDAS BRAHMS PCT) as the entrenched sepsis biomarker standard. It is a broad incumbent comparator because it defines the existing sepsis diagnostic workflow that PSP must displace or supplement across hospital ICUs worldwide.
Direct peers
- Abionic SA: Abionic is LASCCO's exclusive global commercialization partner for the IVD CAPSULE PSP and is itself a point-of-care diagnostics developer. It is directly comparable because it commercializes the same PSP biomarker on its proprietary capsule platform, making it simultaneously peer, partner, and primary revenue conduit for LASCCO.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
LASCCO social profiles
Digital presenceLASCCO compliance and trust
Trust signalCompliance4 records
LASCCO financial estimates
Financial estimateRevenue estimate
Valuation estimate
LASCCO leadership team
Management profileNumber of profiles
Profiles3 records
LASCCO funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
LASCCO M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about LASCCO
What does LASCCO do?
LASCCO SA develops and owns the intellectual property for the Pancreatic Stone Protein (PSP), a biomarker used in a rapid diagnostic test for the early detection of sepsis. The company licenses the commercial rights to its PSP biomarker to Abionic SA for global commercialization and to Fapon for the Chinese market, earning royalties from these partnerships.
Is LASCCO a public or private company?
LASCCO is a private company. It is classified as unknown and is currently operating.
When was LASCCO founded?
LASCCO was founded in 2007. It employs 5,001 to 10,000 people.
Where is LASCCO based?
LASCCO is headquartered in Geneva, Switzerland, in the Europe region.
How does LASCCO make money?
One revenue line is on record: licensing Royalties.
Who are LASCCO's main competitors?
Siemens Healthineers is listed as a peer. Broad incumbents are Roche Diagnostics and bioMérieux. Abionic SA is listed as a direct peer.
Does LASCCO have an API?
No public API is recorded for LASCCO.
What industry is LASCCO in?
LASCCO's product category is In-Vitro Diagnostics (Sepsis Biomarkers). Its primary akta.pro industry code is HLAJAOAM, Global Health Research, Clinical Trials & Product Development Partnerships (PDPs), with a secondary code of HLAGAAAE, Central Laboratory & Clinical Trial Testing CROs. Its NAICS code is 325413 and its SIC code is 2835.